Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review
Journal of Clinical Apheresis · 2024
DOI: 10.1002/jca.22116 ↗At a glance
Systematische Übersicht in Journal of Clinical Apheresis, 2024. Written by Brian D Adkins and 3 co-authors. Institution: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Gemtuzumab, Plasma Exchange, Hemoglobins. 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Gemtuzumab ozogamicin (GO) is a CD33 monoclonal antibody‐drug conjugate currently in use to treat myeloid malignancies. A unique adverse effect of this medication is destruction of CD33 positive macrophages resulting in reduced clearance of free hemoglobin leading to grossly red plasma. This build‐up of free hemoglobin can potentially lead to end organ damage and prevent performance of clinically necessary laboratory evaluation. We present a case of a pediatric patient who developed this adverse effect and was successfully treated with therapeutic plasma exchange (TPE). We also present results from a systematic review of the medical literature and share data from a query of the United States Food and Drug Administration (FDA) Adverse Event Reporting system for GO‐related hemoglobin scavenging impairment. Among reported cases, patients undergoing TPE and those receiving steroids had improved outcomes. Practitioners should be aware of this rare drug side‐effect and the potential utility of TPE for these patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Children's Health System, Dallas, Texas, USA.
- Division of Hematology and Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID profiles: Brian D Adkins
Cite
APA
Adkins, B. D., Noland, D. K., Slone, T., & Sadanand, A. (2024). Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22116
Vancouver
Adkins BD, Noland DK, Slone T, Sadanand A. Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review. Journal of Clinical Apheresis. 2024. doi:10.1002/jca.22116
BibTeX
@article{Adkins2024,
author = {Adkins, Brian D and Noland, Daniel K and Slone, Tamra and Sadanand, Arhanti},
title = {Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review},
journal = {Journal of Clinical Apheresis},
year = {2024},
doi = {10.1002/jca.22116}
}
EUVIMED